Shingrix
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Herpes zoster vaccine (recombinant, adjuvanted)
- Made by
- GlaxoSmithKline Biologicals S.A.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: adults 50 years of age or older; adults 18 years of age or older at increased risk of HZ. The use of Shingrix should be in accordance with official recommendations.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | GlaxoSmithKline Biologicals S.A. |
|---|---|
| Active substance | Herpes zoster vaccine (recombinant, adjuvanted) |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J07BK03 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2018-03-21 |
| Last updated by the regulator | 2026-03-23 |
| EMA product number | EMEA/H/C/004336 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).